非小细胞肺癌分子靶向EGFR-TKI治疗敏感性与治疗耐受性预测筛选的分子显像研究现状及进展

摘要

More than 80％ of lung cancer is non-small cell lung cancer (NSCLC),and the epidermal growth factor receptor (EGFR)-mediated signaling pathway is closely related to the occurrence and development of NSCLC.Small molecule EGFR-tyrosine kinase inhibitors (EGFR-TKI) targeting EGFR have been used in the clinical treatment of NSCLC,and positron emission tomography/computed tomgraphy (PET/CT) imaging can noninvasively monitor the expression and mutation status of EGFR in patients with NSCLC.18F-FDG PET/CT imaging has predictive value for the activation of EGFR mutation and EGFR-TKI treatment efficacy,and in vivo can be directly observed drugs and systemic tumor targeting EGFR combined with the specific circumstances,by PET/CT imaging before and after treatment,to achieve dynamic monitoring,guide the therapy before treatment and treatment of sensitive population screening process,to achieve NSCLC EGFR-TKI precise treatment is essential.%肺癌80％以上为非小细胞肺癌(non-small cell lung cancer,NSCLC),表皮生长因子受体(epidermal growth factor receptor,EGFR)介导的信号通路与NSCLC发生发展密切相关.针对EGFR的小分子EGFR赖氨酸激酶抑制剂(EGFR-tyrosine kinase inhibitor,EGFR-TKI)被应用于NSCLC的临床治疗,正电子发射计算机断层显像(positron emission tomography/computed tomgraphy,PET/CT)能够无创地对NSCLC患者全身EGFP表达及突变状况进行连续动态监测.18F-FDG PET/CT显像对于EGFR活化突变、EGFR-TKI治疗疗效具有预测价值,并且能够在体直接观察到药物与全身肿瘤病灶EGFR靶向结合的具体情况,通过治疗前后的PET-CT显像,实现治疗前高敏人群筛选和治疗全过程的动态监测、治疗策略指导,对实现NSCLC的EGFR-TKI精准治疗至关重要.